Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Table 4 ( Continued ) Characteristic, % Warfarin (n = 183,003 ) * Dabigatran (n = 86,293 ) * Rivaroxaban (n = 106,369 ) * Apixaban (n = 72,921 ) * Maximum Pairwise SMD after Weighting H2-antagonists 5.1 5.0 5.1 5.0 0.00 NSAIDs 14.2 14.1 14.2 14.1 0.00 Proton pump inhibitors 27.2 26.8 27.0 27.0 0.01 SSRI antidepressants 12.9 12.8 12.8 12.8 0.00 Cardiovascular ACEI/ARB 59.1 58.9 59.0 58.9 0.00 Antiarrhythmics 17.0 17.1 17.0 17.1 0.00 Anticoagulants (injectable) 8.7 8.6 8.6 8.6 0.00 Anti-platelets 14.9 14.4 14.6 14.5 0.01 Beta-blockers 67.7 67.7 67.6 67.8 0.00 Calcium channel blockers 41.9 41.8 41.8 41.8 0.00 Digoxin 11.7 11.5 11.5 11.4 0.01 Diuretics Loop 24.1 23.6 23.7 23.9 0.01 Potassium sparing 8.0 8.0 8.0 8.0 0.00 Thiazide 28.6 28.6 28.6 28.6 0.00 Nitrates 9.4 9.1 9.1 9.1 0.01 Statins 58.6 58.5 58.5 58.4 0.00 Fibrates 4.4 4.4 4.4 4.3 0.00 Diabetes-related Insulin 6.6 6.5 6.5 6.5 0.01 Metformin 15.3 15.2 15.3 15.1 0.00 Sulfonylureas 8.6 8.5 8.6 8.5 0.00 Other 6.0 5.9 6.0 6.0 0.00 Metabolic inhibitors x Amiodarone 9.4 9.2 9.2 9.3 0.01 Dronedarone 3.6 3.6 3.6 3.6 0.00 Prescriber specialty Cardiology 55.1 55.6 55.3 55.4 0.01 Family medicine 8.4 8.2 8.3 8.2 0.01 Internal medicine 19.2 19.1 19.1 19.2 0.00 Other 17.4 17.1 17.3 17.2 0.01 Low income 17.3 16.8 17.0 16.9 0.01 Geographic region Northeast 18.9 19.0 19.0 19.1 0.00 South 43.3 43.4 43.4 43.2 0.00 Midwest 21.3 21.2 21.2 21.3 0.00 West 16.4 16.4 16.5 16.5 0.00 Rural metropolitan statistical area 23.4 23.0 23.2 23.0 0.01 Medical comorbidities Alcohol abuse 1.9 1.9 1.9 2.0 0.00 Anemia 20.0 19.6 19.7 19.9 0.01 Chronic liver disease 2.0 2.0 1.9 2.0 0.00 COPD 19.3 18.8 19.0 19.0 0.01 Dementia 3.6 3.5 3.5 3.5 0.01 Gout 5.6 5.6 5.6 5.6 0.00 Malignancy 23.3 23.3 23.3 23.4 0.00 Peripheral vascular disease 16.9 16.5 16.6 16.7 0.01 Other medical conditions Home health care 9.6 9.2 9.3 9.4 0.01 Home oxygen 7.6 7.4 7.5 7.5 0.01 Wheelchair use 2.0 1.9 2.0 1.9 0.01 Hospitalizations (non-bleeds) 38.1 37.4 37.4 38.0 0.01 Emergency department visits in past 0-30 days (n) 0 86.2 86.3 86.4 86.3 0.01 1 12.4 12.3 12.2 12.3 0.00 ≥ 2 1.4 1.4 1.4 1.4 0.00 Graham et al Comparative Safety and Effectiveness of Anticoagulants in Atrial Fibrillation 9.e4